Overview
BiotechPhase 2MDMALSDpsilocybin
Spun out from MAPS to develop MDMA-assisted therapy. After FDA declined approval in August 2024, underwent significant restructuring. Continuing to pursue MDMA therapy for PTSD.
Visit WebsiteSan Jose, CA
3
Clinical Trials
2024
Founded
60
Employees
0
Open Roles
Open Positions
No open positions at this time
Research Areas
Clinical Pipeline(3)
Completed·Phase 2·MDMA
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
Midomafetamine HClPTSD
Completed·Phase 2·LSD
Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety
200 mcg LSDAnxiety
Withdrawn·Phase 2·psilocybin
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
psilocybinAnxiety